On November 28th, AbbVie China announced that the two newly approved indications for the immune innovation product Ruifu (Upatinib Extended Release Tablets) in 2023 have entered the new version of the national medical insurance catalog released on the same day, for the treatment of patients with ankylosing spondylitis (AS) and radiologically negative axial spondyloarthritis (nr-ax5pA).